Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa

BACKGROUND: Oxaliplatin and 5-fluorouracil (5-FU) currently form the backbone of conservative treatment in patients with metastatic colorectal cancer. Tumour responses to these agents are highly variable, but the underlying mechanisms are poorly understood. Our previous results have indicated that o...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruijn, M T, Raats, D A E, Hoogwater, F J H, van Houdt, W J, Cameron, K, Medema, J P, Borel Rinkes, I H M, Kranenburg, O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856010/
https://www.ncbi.nlm.nih.gov/pubmed/20354524
http://dx.doi.org/10.1038/sj.bjc.6605633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856010/
https://www.ncbi.nlm.nih.gov/pubmed/20354524
http://dx.doi.org/10.1038/sj.bjc.6605633

Ejemplares similares